Regional differences in physicians’ behavior and factors influencing the intensity of PCSK9 inhibitor therapy with alirocumab: a subanalysis of the ODYSSEY APPRISE study

Regional differences in physicians’ behavior and factors influencing the intensity of PCSK9 inhibitor therapy with alirocumab: a subanalysis of the ODYSSEY APPRISE study

BackgroundDespite better accessibility of the effective lipid-lowering therapies, only about 20% of patients at very high cardiovascular risk achieve the low-density lipoprotein cholesterol (LDL-C) goals. There is a large disparity between European countries with worse results observed for the Centr...

Full description

Bibliographic Details
Main Authors: Maciej Banach, Joanna Lewek, Kaja Pol, Daniel Rabczenko, Serban M. Balanescu, Vladimir Blaha, Richard Ceska, Piotr Jankowski, Stanisław Surma, Genovefa Kolovou, Evangelos Liberopoulos, Florin Mitu, Magda Mitu, Franjo Husam Naji, Gyorgy Paragh, Magdalena Popławska, Michal Vrablik, Daniel Pella
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-06-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
alirocumab
LDL-C
PCKS9 inhibition
therapy goals
therapy intensity
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2023.1206551/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2023.1206551/full

Similar Items